PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
Having restructured its balance sheet through the conclusion of court-led rehabilitation and a KRW 160 billion investment from the Taekwang Industries–UAMCO consortium, Dongsung Pharmaceutical faces the task of restoring core profitability after trading resumed.
The company escaped the immediate delisting crisis after court approval of its rehabilitation plan in March 2026, plan conclusion in May, and trading resumption on July 30.
The company raised a total of KRW 160 billion (KRW 70 billion rights offering plus KRW 90 billion bonds) to repay debt, but partial capital impairment persists due to accumulated deficit.
FY2025 annual revenue was KRW 87.17 billion, with an operating loss of KRW 10.12 billion and a controlling shareholder net loss of KRW 25.74 billion, marking a widened deficit.
After a marginal operating profit of KRW 0.29 billion in 1Q26, the company swung back to an operating loss of KRW 2.03 billion and a net loss of KRW 5.89 billion in 2Q26, reflecting high earnings volatility.
A new board centered on the Taekwang Industries–UAMCO consortium and a newly appointed CEO with pharmaceutical industry experience have begun management normalization efforts.
Founded in 1957, Dongsung Pharmaceutical is a 70-year-old mid-sized pharmaceutical company with in-house manufacturing capability at its Asan plant, producing pharmaceuticals, hair-dye products, and cosmetics.
According to the company, its business mix consists of roughly 30% hair-dye products, 28.4% prescription drugs (ETC), 33% over-the-counter drugs (OTC), and about 9% health supplements and cosmetics.
Its flagship products include the anti-diarrheal 'Jungnohwan' (launched in 1972, with annual sales in the KRW 10 billion range), the hair-dye brand 'Seven Eight', the hair-loss treatment 'Minoxidil', and the anti-inflammatory 'Loxo N Gel'.
In January 2026, Taekwang Industries formed a consortium with Union Asset Management Company (UAMCO) to acquire Dongsung, with the Taekwang group stating its intent to expand from its chemical and textile-centered portfolio into the beauty and healthcare sector.
The plan reportedly includes leveraging Taekwang's home-shopping and media-commerce distribution infrastructure to broaden sales channels while streamlining selling and administrative expenses.
On the pipeline side, the photosensitizer-based anticancer candidate 'Ponozen' (DSP-1944) is in Phase 2 clinical trials, and R&D investment is expected to expand following the acquisition. However, the R&D-to-sales ratio has reportedly remained low, meaning pipeline results may take time to materialize.
Competitively, legacy products such as Jungnohwan and Seven Eight retain solid brand recognition, but the company faces a relatively heavy selling expense burden due to high distribution channel fees.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩20B | -₩4.2B | −20.8% |
| 2025Q3 | ₩21.8B | ₩400M | 1.9% |
| 2025Q4 | ₩19.1B | -₩7.1B | −37.3% |
| 2026Q1 | ₩19.1B | ₩300M | 1.5% |
| 2026Q2 | ₩22.1B | -₩2B | −9.2% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩93.3B | -₩3.1B | -₩2.1B | −3.3% | −5.0% | 151.6% |
| 2023 | ₩88.6B | ₩600M | -₩2.1B | 0.7% | −5.2% | 188.9% |
| 2024 | ₩88.4B | -₩5.7B | -₩14.6B | −6.5% | −33.1% | 219.9% |
| 2025 | ₩87.2B | -₩10.1B | -₩25.7B | −11.6% | −110.1% | 620.7% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23
Annual revenue declined gradually for four consecutive years, from KRW 93.33 billion in 2022 to KRW 88.59 billion in 2023, KRW 88.45 billion in 2024, and KRW 87.17 billion in 2025.
Operating profit briefly turned positive in 2023 at KRW 0.60 billion after a loss of KRW 3.10 billion in 2022, but swung back into losses of KRW 5.73 billion in 2024 and KRW 10.12 billion in 2025, with the operating margin deteriorating from 0.7% in 2023 to -11.6% in 2025.
The controlling-shareholder net loss widened sharply from KRW 2.07 billion in 2023 to KRW 14.57 billion in 2024 and KRW 25.74 billion in 2025, a pattern that appears to reflect both the wider operating loss and one-off costs tied to the balance-sheet restructuring process.
On a quarterly basis, 2Q25 saw an operating loss of KRW 4.15 billion but a much larger net loss of KRW 18.79 billion, before the company briefly returned to profit in 3Q25 with an operating profit of KRW 0.41 billion and net income of KRW 0.11 billion.
The loss then widened again in 4Q25 to an operating loss of KRW 7.12 billion and a net loss of KRW 5.75 billion.
In 1Q26 the company posted a marginal operating profit of KRW 0.29 billion and near-breakeven net income of KRW 0.014 billion, only to swing back to an operating loss of KRW 2.03 billion and a net loss of KRW 5.89 billion in 2Q26.
Over the trailing four quarters (3Q25–2Q26), the company remains in a net loss position, and the large quarter-to-quarter swings suggest the earnings trend has not yet stabilized.
Operating cash flow was negative every year from 2022 through 2025, indicating weakened cash generation alongside the absence of sustained profit.
Korea's small and mid-cap pharmaceutical sector is structurally burdened by heavy selling and administrative costs on OTC, hair-dye, and cosmetic consumer products amid drug price cuts and sluggish domestic consumption.
Many peers of similar scale to Dongsung face profitability pressure with SG&A ratios in the 40-50% range, an issue also flagged in industry analyses such as Dealsite's coverage.
At the same time, tightened delisting standards from financial regulators have increased the number of small-cap names subject to managed-stock or delisting review for falling below market-cap or share-price thresholds, weighing on investor sentiment across the small-cap pharma/bio sector broadly.
Reports note that a notably high share of companies subjected to recent listing-eligibility reviews were pharma/bio names.
In this environment, Dongsung is relatively better positioned in terms of capital-impairment and liquidity risk after securing funding and distribution infrastructure from the Taekwang-UAMCO consortium, but improving its core profit structure remains a challenge shared across the industry.
Expanding overseas exports is a common growth strategy among domestic mid-sized pharma companies, and Dongsung has a track record of exporting products like Jungnohwan and Minoxidil to Southeast Asia and Greater China.
Still, with top-line revenue essentially stagnant, the key point to watch is less about industry-wide positioning and more about the company's execution on profitability after its financial normalization.
Following the conclusion of court-led rehabilitation and the resumption of trading, the company has stated its intention to expand sales and strengthen profitability on the back of a more stable financial structure.
After the Taekwang acquisition, proposed profitability measures include a review of ODM/OEM conversion utilizing Picostech, an entity backed by UAMCO, along with production-line optimization and SG&A efficiency improvements.
The newly appointed CEO, who previously held roles at Pharmanovia Korea, Takeda Korea, and AstraZeneca, has reportedly set organizational culture and profit-structure improvement as management priorities.
On the pipeline side, Phase 2 trials for the anticancer candidate Ponozen are ongoing, with reports suggesting Taekwang's investment could provide a more stable development environment. However, none of these plans have yet been quantified into concrete revenue or profit guidance.
Given that the company swung back into loss in 2Q26 after a marginal profit in 1Q26, it may take additional time before normalization effects are reflected consistently in results.
Subsequent steps in financial and governance normalization—including whether partial capital impairment is resolved, current liability management, and the conclusion of litigation related to the past ownership dispute—remain variables that could affect future performance and the share price.
Because Dongsung has posted net losses in most recent years, earnings-based valuation metrics have often been difficult to apply in the conventional sense. On the asset side, the ongoing partial capital impairment is a factor that should be weighed when assessing the share price relative to net assets.
The company appears to have no recent dividend payment record, suggesting market attention is focused less on dividend appeal and more on whether the balance sheet normalizes and profitability recovers.
Since trading resumed, the share price has been reflecting two offsetting forces at once: the positive financial event of rehabilitation conclusion and capital infusion, and the still-ongoing core operating loss.
Going forward, valuation assessments are likely to hinge heavily on whether earnings re-enter a stable profit zone and whether the capital impairment is resolved.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23
The combined KRW 160 billion inflow from a KRW 70 billion rights offering and KRW 90 billion in bonds sharply increased cash and cash equivalents, and debt repayment under the rehabilitation plan has been completed.
With the rehabilitation process formally concluded and trading resumed, the most urgent delisting risk has been addressed for now, though partial capital impairment means normalization is not yet complete.
Taekwang Industries has indicated plans to broaden Dongsung's sales channels using affiliate distribution infrastructure such as home shopping and media commerce.
A review of ODM/OEM conversion through UAMCO-backed Picostech has also been proposed as an SG&A efficiency measure, though whether these synergies materialize in actual revenue and cost figures requires further confirmation.
Jungnohwan, Seven Eight, and Minoxidil are long-established, well-recognized brands, with Jungnohwan's annual sales having surpassed the KRW 10 billion mark.
The company has a track record of expanding exports to Southeast Asia and Greater China, leaving room for further overseas channel expansion, although overall revenue has recently shown a stagnant trend.
The FY2025 operating loss widened to KRW 10.12 billion from KRW 5.73 billion the prior year, and the company has been flagged for an SG&A structure that exceeds gross profit.
In 2026, the marginal 1Q profit was followed by another operating loss in 2Q, meaning the sustainability of any earnings improvement has not yet been confirmed, while revenue itself has declined modestly for four straight years.
The FY2025 debt ratio jumped to 620.7% from 219.9% the prior year, and partial capital impairment persists due to an accumulated deficit.
Even after the large capital infusion, current liabilities are reported to have grown as well, leaving debt management as an ongoing challenge; it remains premature to conclude the balance sheet has fully normalized.
Corporate ethics issues have arisen from the past ownership dispute, including embezzlement/breach-of-trust allegations and a corrective order related to rebate practices, and the company received a low ESG rating.
Reports also indicate that litigation such as an immediate appeal against the rehabilitation plan approval has not been fully resolved, meaning whether the new management structure stabilizes remains to be seen.
Alongside continued partial capital impairment and an elevated debt ratio, current liabilities have grown even after the large capital infusion.
Operating cash flow has been negative for multiple consecutive years, indicating weak internal cash generation, and it will be worth monitoring whether further fundraising or asset sales become necessary.
The company was granted an improvement period during a listing-eligibility review before receiving a listing-maintenance decision and resuming trading in July 2026.
Amid tightening delisting standards from financial regulators, regulatory risk such as re-designation as a managed stock could resurface if share price, market cap, or financial metrics fall below thresholds again, warranting continued monitoring of KOSPI listing requirements.
The anticancer candidate Ponozen is still in Phase 2 trials, meaning commercialization could take considerable time, and the R&D-to-sales ratio has reportedly remained low, potentially limiting investment capacity.
The extent to which Taekwang's stated plan to expand R&D investment will actually be executed has not yet been specified, and delays or disappointing trial results could necessitate a reassessment of pipeline value.
The 3Q26 report will show whether revenue and operating profit/loss trends improve from the 2Q loss and whether the SG&A ratio declines.
Watch for the resolution of remaining litigation such as an immediate appeal related to the rehabilitation plan approval, and for developments tied to the aftermath of the ownership dispute, including embezzlement allegations and rebate-related matters.
Check for progress updates or additional academic disclosures on the Phase 2 clinical trial of the anticancer candidate Ponozen.
In the FY2026 annual results, whether partial capital impairment is resolved and how much the debt ratio declines from 2025's elevated level will be key indicators of financial normalization.
Following its May 2025 trading suspension and rehabilitation filing, Dongsung Pharmaceutical went through a sequence of normalization steps built on the KRW 160 billion investment from the Taekwang Industries–UAMCO consortium: rehabilitation plan approval in March 2026, plan conclusion in May, and trading resumption in July.
The capital infusion has eased some financial risk, but partial capital impairment and an elevated debt ratio remain unresolved challenges.
Core operations widened to a FY2025 operating loss of KRW 10.12 billion and a net loss of KRW 25.74 billion, and results have since oscillated between a marginal 1Q26 profit and a renewed 2Q26 loss, without yet showing a clear improving trend.
Potential mid- to long-term growth drivers—leveraging Taekwang's distribution infrastructure, SG&A efficiency measures, and the Ponozen anticancer pipeline—have been proposed but have not yet translated into concrete numerical guidance.
On the governance side, issues stemming from the past ownership dispute, including litigation and a low ESG rating, also remain to be resolved.
Ultimately, the key points to watch going forward are whether financial normalization is completed (resolution of capital impairment) and whether core profitability achieves a stable recovery.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.